REVB Revelation Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REVB

Price (delayed)

$2.35

Market cap

$3.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.53

Enterprise value

-$8.15M

Highlights
The net income has shrunk by 114% QoQ but it has soared by 99% YoY
The EPS has dropped by 100% since the previous quarter but it has surged by 100% year-on-year
REVB's equity is down by 25% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of REVB
Market
Shares outstanding
1.63M
Market cap
$3.84M
Enterprise value
-$8.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$120,254
EBITDA
-$95,205
Free cash flow
-$7.29M
Per share
EPS
-$0.53
Free cash flow per share
-$31.87
Book value per share
$31.67
Revenue per share
$0
TBVPS
$53.41
Balance sheet
Total assets
$12.21M
Total liabilities
$5.56M
Debt
$0
Equity
$6.65M
Working capital
$6.58M
Liquidity
Debt to equity
0
Current ratio
2.18
Quick ratio
2.15
Net debt/EBITDA
125.96
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-0.8%
Return on equity
-1.3%
Return on invested capital
N/A
Return on capital employed
-1.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REVB stock price

How has the Revelation Biosciences stock price performed over time
Intraday
9.3%
1 week
9.81%
1 month
-9.27%
1 year
-92.11%
YTD
-84.36%
QTD
-14.23%

Financial performance

How have Revelation Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.66M
Net income
-$120,254
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 114% QoQ but it has soared by 99% YoY
REVB's operating income is up by 20% YoY but it is down by 15% from the previous quarter

Growth

What is Revelation Biosciences's growth rate over time

Valuation

What is Revelation Biosciences stock price valuation
P/E
N/A
P/B
0.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 100% since the previous quarter but it has surged by 100% year-on-year
The price to book (P/B) is 86% lower than the last 4 quarters average of 0.5
REVB's equity is down by 25% since the previous quarter

Efficiency

How efficient is Revelation Biosciences business performance
REVB's return on equity has dropped by 112% since the previous quarter but it has surged by 100% year-on-year
The company's return on assets has shrunk by 112% QoQ but it has surged by 100% YoY

Dividends

What is REVB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REVB.

Financial health

How did Revelation Biosciences financials performed over time
The company's total assets is 119% higher than its total liabilities
The company's total assets has surged by 122% YoY but it fell by 14% QoQ
The quick ratio has soared by 82% year-on-year but it is down by 17% since the previous quarter
The debt is 100% less than the equity
REVB's equity is down by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.